Skip to content

Advertisement

Open Access

The use of historical priors to improve the efficiency of phase II clinical trials with time-to-event endpoints

  • Richard Jackson1,
  • Trevor Cox1 and
  • Catrin Tudur-Smith1
Trials201314(Suppl 1):P53

https://doi.org/10.1186/1745-6215-14-S1-P53

Published: 29 November 2013

Keywords

Survival ProbabilityExpert OpinionPrevious TrialExponential ModelHistorical Information

We explore the possibility of incorporating historical information, which may take the form of data from previous trials, summary information or information derived from expert opinion into the design of phase II clinical trials with a time-to-event endpoint.

We model the survival data by means of the Piecewise Exponential Model and introduce a method by which a prior baseline hazard function is derived from summary information given by survival probabilities at given time points. We explore the use of gamma priors for the baseline hazard function as well as locally flat priors, where prior opinion of parameter estimates are equal within a given set of bounds.

We argue that placing priors on such information can improve decision making process by increasing the precision of the main parameter of interest, the hazard ratio. We further show that the influence of such a prior increases as more data are attributed to the experimental arm of a trial and argue that a prior on the baseline hazard function to be more appropriate than priors placed on the hazard ratio as there is typically much more information available on this aspect of a trial.

We illustrate the methodology via a simulation study to show how such an approach can improve measures such as the alpha level and power of comparisons between two therapies and make some arguments toward the case for unequal allocations. Applications to the ViP trial currently being run at the Liverpool Cancer Trials Unit are also discussed.

Authors’ Affiliations

(1)
University of Liverpool, Liverpool, UK

Copyright

© Jackson et al; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.

Advertisement